Anne Paccaly - Concepedia

Author

Anne Paccaly

Also Known As

A PACCALY, A Paccaly, A. J. Paccaly, A. Paccaly, A.J. Paccaly, Anne J Paccaly, Anne J. Paccaly, Anne Josee Paccaly, Anne Paccaly, Marie-Laure Ozoux

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Regeneron (United States)Sanofi (United States)Sanofi (France)Sarah Cannon South Texas Accelerated Research Therapeutics

About

Anne Paccaly is an author at Regeneron (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	207
2	Immunology	4	4	122
3	Health Sciences	2	2	31
4	Pathology	2	2	41
5	Clinical Immunology	1	1	63

Anne Paccaly

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Nature Medicine	2022	268
Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients Andreas H. Diacon, Rodney Dawson, M. Hanekom, The International Journal of Tuberculosis and Lung Disease	2011	203
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis Paul Emery, Juan Rondon, Janie Parrino, Lara D. Veeken	2018	123
Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose Tarek A. Leil, Yilin Feng, L Zhang, Clinical Pharmacology & Therapeutics	2010	92
Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis Eun Bong Lee, Nikki Daskalakis, Christine Xu, Clinical Pharmacokinetics	2016	76
Effect of an NK <sub>1</sub> /NK <sub>2</sub> Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma J. D. Boot, Sanne de Haas, S. Tarasevych, American Journal of Respiratory and Critical Care Medicine	2006	68
Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects Suresh Mallikaarjun, Charles D. Wells, Carolyn Petersen, Antimicrobial Agents and Chemotherapy Healthy SubjectsPharmacotherapyPharmacodynamic ModelingDrug ResistanceMedicinal Chemistry	2016	65
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies Kyriakos P. Papadopoulos, Melissa L. Johnson, A. Craig Lockhart, Clinical Cancer Research	2019	65
Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters Christine Xu, Ashique Rafique, Terra Potocky, The Journal of Clinical Pharmacology Clinical ImmunologyReceptor OccupancyImmunologyImmune RegulationImmunologic Mechanism	2020	63
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate Anne Paccaly, Pavel Kovalenko, Janie Parrino, The Journal of Clinical Pharmacology	2020	36

Page 1